International Journal of Pharmaceutical and Biological Science Archive

Liposomes for Targeted Delivery of Thrombolytic and Antithrombin Drug

2025-05-10T06:04:41+00:00

Targeted administration of antithrombotic (thrombolytic) medications is expected to boost their efficacy and lessen adverse effects, especially in the case of thrombolytic enzymes. Liposomes, phospholipid nanosized bilayered membrane bubbles have attracted a lot of attention.as pharmacological vehicles for genes and medications. Specifically, a number of attempts have been proposed to deliver antithrombotic drugs using liposomes. This study examines the information that is currently available about the use of liposomes, such as those that are ligand-specific, for the delivery Using thrombolytic and antithrombotic medications to boost their effectiveness and lessen adverse effects. The published works on the topic with antithrombotic agent-loaded liposomes, primarily during the final 10 to 15 years will be talked about. In conclusion, liposomes containing a variety of despite the fact that antithrombotic medications have been the focus of a substantial amount of experimental publications, they are scarcely viable options in the foreseeable future for clinical use.

Key words: antithrombotic drugs, liposomes, targeted delivery, thrombolysis anticoagulant.

Simultaneous Determination of Sitagliptin and Simvastatin in Tablet Dosage Form by a Validated Rp-Hplc Method

2025-05-10T11:54:31+00:00

A simple, sensitive, and precise rp-hplc method for the simultaneous estimation of sitagliptin (sit) and simvastatin (sim) combined dosage form has been developed and validated. The components were well separated using agilent c8 (4.6x150mm, 3.5µm) column using phosphate buffer (ph-6.26): acetonitrile in the ratio 25:75 as mobile phase at a flow rate of .8 ml/min. The eluents were detected at 254nm using uv detector. The retention times of sit and sim were found to be 2.475 min and 6.528 min for simvastatin and sitagliptin respectively. The linearity was observed in the range of 80-120 µg/ml for sit and 16- 24µg/ml for sim. The marketed dosage form was analyzed by using the developed method and the percent content of sit and sim were found to be 99.67– 100.27 % and 99.42 – 100.54%. The developed method was validated for parameters like system suitability, specificity, linearity, accuracy, precision, ruggedness and robustness as per ich guidelines and the results were found to be within the limits. The validated method was used for the stability studies (short, long and auto sampler) and forced degradation studies (acidic, alkaline, oxidative and photolytic). Both sit and sim were found to be stable in all conditions. This validated method can be used for the routine quality control testing of sit and sim combined dosage form.

Keywords: Sitagliptin, Simvastatin, Simultaneous estimation.

Development and Validation of RP-HPLC Method for the Determination of Bilastine

2025-05-12T06:31:59+00:00

A new RP-HPLC method was developed for the estimation of bilastine tablet and it was validated as per ICH guidelines. The chromatogram for was found to be satisfactory on symmetry Aligent C-18 (250x4.6mm) 5µ column using Buffer: (Dipotassium hydrogen phosphate): Acetonitrile (pH adjusted at 7.0 using Orthophosphoric acid) in the ratio of 50:50 v/v at a flow rate of 1ml/min at 215nm. The peak of within limits was found well separated at 2.7 min. The retention time of bilastine were found to be 2.70 min. The system suitability parameters proved that the proposed method is suitable for estimation of bilastine. The method was found to be linear in the range of 5-20 μg/ml shows a correlation coefficient of 0.999 for a peak. The precision of the method was good and the recovery of drugs is well within the acceptance limits of 80-120%. The LOD was found to be 0.40 μg/ml and LOQ was found to be 1.42 μg/ml for bilastine. The developed method was validated for various parameters as per ICH guidelines like system suitability, specificity, linearity, system precision, method precision, accuracy, ruggedness and robustness.

Keywords: Bilastine, RP-HPLC, validation, estimation.

Development and Validation of RP-HPLC Method for the Determination of Sorafenib Tablet

2025-05-12T06:29:58+00:00

Sorafenib, an oral multi-kinase inhibitor, is an extensively utilized in oncology for its antineoplastic Department ofPharmaceutical Chemistry, Maharshi Arvind College of Pharmacy, Ambabari, Jaipur-302039, Rajasthan, India properties. Accurate quantification of Sorafenib in pharmaceutical formulations is critical for quality control and therapeutic efficacy. Reverse phase high-performance liquid chromatography offers a sensitive, rapid, precise, accurate high-performanceliquid chromatographic method for the estimation of Sorafenib (SOR) in the tablet dosage form. Chromatographic separation of SOR was carried out utilizing thermo-scientific model C18 column (4.6 mm i.d. X 250 mm; 5µm particlesize) (based on 99.99 % ultra-high purity silica) using mobile phase that consisting of acetonitrile: methanol (40:60 v/v) ata flow rate of 1.0 mL/min. The absorption maximum (λmax) of SOR in the mobile phase was found to be 266 nm. It had a retention time of 3.222 min. The calibration curve was in linear function of the drug in the concentration range of 2-10 µg/mL (r2 = 0.999) for the optimized method. The regression equation for SOR was found to be Y = 68228 x + 8071. The Detection Limit (DL) & Quantitation Limit (QL) results of SOR were found to be 0.525 µg/mL and 1.595 µg/mL respectively. The developed method was validated in pursuance of ICH Q2 (R1) guidelines. The method was linear, precise, accurate with recoveries in the range of 98 - 102 %, and minimum values of % RSD indicate the accuracy of themethod. The detailed quantitative results of the study show that this method is robust, precise, accurate, and cost-effective.Thus, the developed RP-HPLC method is reproducible and demonstrating its suitability for routine analysis of Sorafenib in pharmaceutical formulations.

Keywords: Sorafenib, RP-HPLC, Pharmaceutical formulation, Validation.